Key result
Treatment with imatinib mesylate successfully reversed cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome.
Why the study?
Does imatinib mesylate reverse cardiac abnormalities in a patient with idiopathic hypereosinophilic syndrome?
Case Report (n=1)
Does imatinib mesylate reverse cardiac abnormalities in a patient with idiopathic hypereosinophilic syndrome?
Imatinib mesylate successfully reversed cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome mimicking acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for imatinib in hypereosinophilic cardiac disease; larger studies needed before clinical adoption.
We report a case of idiopathic hypereosinophilic syndrome in a young man, who showed symptoms and electrocardiographic findings mimicking an acute coronary syndrome. Two-dimensional echocardiography, together with laboratory data, allowed us to make the diagnosis and to start a treatment with imatinib mesylate, a 2-phenylamonopyrimidine-based tyrosine kinase inhibitor, which reversed the cardiac abnormalities.
No takes yet. Share an insight, caveat, or question.
Luigi Ascione (2004) conducted a case report in idiopathic hypereosinophilic syndrome (n=1). imatinib mesylate was evaluated on reversal of cardiac abnormalities. Treatment with imatinib mesylate successfully reversed cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: